What’s new

• Court-approved resolution plan implementation delayed past 10 July 2026 deadline
• Successful resolution applicant Beaufond Industries has not completed terms as of 14 July
• Monitoring committee meeting being convened to decide next steps

Why it matters

For a company already in corporate insolvency, missing a court-set deadline for a ₹70 crore infusion is a material negative. The delay raises the risk that the resolution plan could collapse, potentially pushing Kobo toward liquidation and wiping out any residual shareholder value.

What we’re watching

• Outcome of the monitoring committee meeting and any revised timeline
• Whether Beaufond can still implement the plan or if the NCLT will seek a new resolution
• Liquidation risk if the plan fails

The full read

Kobo Biotech's court-approved resolution plan hit a wall. The ₹70.11 crore infusion from Beaufond Industries was due by 10 July 2026, 60 days after the NCLT Hyderabad approved it. As of 14 July, the applicant hadn't completed the terms. The company has convened a monitoring committee to decide what comes next. For a nano-cap already in insolvency, a missed deadline on a lifeline of this size is a blow. It raises the question of whether the plan can survive — and if not, whether liquidation is the next stop. Shareholder value hangs on the committee's next move.

Primary source: BSE · NSE